Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease
At the time of assay, the growth medium was replaced with HBSS, supplemented with 10 mM HEPES and 0.1% (w/v) ovalbumin and incubated at room temperature for 30 min
Current NHS eligibility criteria for semaglutide 2.4 mg (Wegovy) for weight management, according to NICE TA875, include: Body Mass Index (BMI) 35 kg/m with at least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea) For people from certain high-risk ethnic groups (such as South Asian, Chinese, Black African, or African-Caribbean), lower BMI thresholds apply (typically reduced by 2.5 kg/m) Treatment must be prescribed within specialist weight management services only Treatment is limited to a maximum duration of 2 years Must be used as an adjunct to a reduced-calorie diet and increased physical activity Liraglutide 3 mg (Saxenda) availability varies significantly across NHS regions and is not routinely commissioned in many areas
Improved fat oxidation enhances overall endurance and helps prevent the accumulation of lactic acid, which often causes muscle fatigue during exercise
